Clinical Trial Update: Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer [Phase 2]

View source ↗

Summary

A Phase 2 single-arm trial evaluating QL1706 combined with lenvatinib and nab-paclitaxel in advanced refractory penile cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Penile Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• LENVIMA (lenvatinib)
• QL1706

Snippet

Sponsor: Sun Yat-sen University | Conditions: Penile Cancer | Phase 2 | Status: NOT_YET_RECRUITING